Abstract
A 7-valent pneumococcal conjugate vaccine (PCV7; Prevnar) that protects against invasive infection by the seven most common serotypes of Streptococcus pneumoniae was licensed in February 2000. Confirmation of the vaccine's benefits now has been published. In a comparison of 2001 data with data from 1994-2000 (gathered from eight U.S. children's hospitals), researchers reported an overall yearly 58% reduction in invasive pneumococcal infections (IPI) such as meningitis, pneumonia, and bacteremia among children younger than …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
